The post-Humira story is now product-specific
AbbVie’s patent narrative was dominated by Humira. The company built one of the industry’s most watched exclusivity estates by combining dense patent coverage, regulatory exclusivity, litigation, and settlement strategy around a single mega-blockbuster. That period has changed.
The strategic question is no longer simply how many patents AbbVie owns. The more useful question is where protection remains commercially meaningful, where the entry window is becoming realistic, and which assets AbbVie is likely to defend most aggressively. That product-specific lens is essential for IP teams, generic manufacturers, 505(b)(2) strategists, biosimilar developers, and competitive-intelligence teams.
Portfolio attrition creates watch points, not automatic weakness
Large pharmaceutical portfolios naturally shed assets. A lapsed or abandoned patent can reflect a discontinued program, weak claim scope, a narrower commercial opportunity, or a deliberate decision to spend only on stronger family members. Still, attrition is strategically useful because it highlights where a defensive perimeter may be thinning.
| Status signal | Count | Strategic implication |
| Lapsed due to non-payment of fees | 283 | May indicate lower-priority assets, discontinued programs, or spend concentration on stronger families. |
| Abandoned during prosecution | 243 | May indicate claim-scope challenges, reduced commercial relevance, or a pivot away from the original invention area. |
This is where proactive monitoring becomes valuable. Changes in maintenance fees, prosecution status, terminal disclaimers, continuation filings, Orange Book listings, or litigation can significantly alter the competitive landscape long before a drug’s exclusivity expires. Tracking these updates in real time with Elixir helps companies stay ahead of emerging risks and opportunities.
Track Every Patent Move in Real Time Across 70+ Jurisdictions with Elixir
Commercial exposure shows where patent signals matter most
AbbVie’s latest full-year results show why the post-Humira portfolio requires an asset-level lens. In 2025, AbbVie reported $61.160 billion in net revenues. Growth was led by immunology assets such as Skyrizi and Rinvoq, while neuroscience and migraine assets also remained strategically important.
AbbVie’s Top Revenue-Generating Drugs and Their Patent Protection
AbbVie’s commercial performance is increasingly concentrated in a small group of high-value drugs. The table below highlights the company’s top revenue-generating products, their key U.S. patents, and the latest patent expiry dates. Together, these data points provide a quick view of where AbbVie retains long-term patent protection and which assets may face competitive pressure sooner.
| Drug | Estimate Revenue | NDA Number | Patent Number | Latest Patent Expiry |
| Rinvoq | $4.3B | 211675 | US8962629B2 US10550126B2 US11512092B2 US11365198B2 US11773106B2 US11976077B2 US11524964B2 US11607411B2 US11564922B2 US11795175B2 US11535624B2 US11535625B2 US11535626B2 US12365689B2 US11993605B2 US11993606B2 US11767326B2 US10995095B2 US10597400B2 US11780848B2 US12570664B2 USRE47221B2 US12110298B2 US11661425B2 US12091415B2 US10981924B2 US11198697B2 US10981923B2 US12103933B2 US11718627B2 US10344036B2 US11186584B2 US11773105B2 US11680069B2 US10202393B2 US9951080B2 US12134621B2 US12077545B2 US11787815B2 US11780847B2 US9963459B2 US12116373B2 US10730883B2 US12110297B2 US10519164B2 | Jan 15, 2031 |
| Vraylar | $3.6B | 204370 | US7737142B2 USRE47350B2 USRE49110B2 USRE49302B2 US7943621B2 | Dec 16, 2028 |
| Venclexta | $2.3B | 208573 | US9539251B2 US9174982B2 US11413282B2 US11590128B2 US10993942B2 US11110087B2 US8546399B2 US10730873B2 US11369599B2 US8722657B2 | May 26, 2030 |
| Namzaric | $1.5B | 206439 | US8039009B2 US8058291B2 | Mar 24, 2029 |
| Linzess | $1.2B | 202811 | US7304036B2 US9708371B2 US8748573B2 US8933030B2 US10702576B2 US8802628B2 US10675325B2 | Aug 30, 2026 |
| Restasis | $1.1B | 50790 | US8292129B2 US9676525B2 US9669974B2 US8561859B2 | Feb 25, 2031 |
| Synthroid | $1.0B | 21402 | – | – |
| Ubrelvy | $0.9B | 211765 | US8754096B2 US9499545B2 US9833448B2 US11717515B2 US12070450B2 US12329750B2 US12194030B2 US11857542B2 US12220408B2 US12458632B2 US8912210B2 US12168004B2 US11925709B2 US12458633B2 US10117836B2 US12310953B2 | Nov 10, 2031 |
| Savella | $0.7B | 22256 | US7994220B2 | Sep 19, 2029 |
| Depakote ER | $0.6B | 21168 | – | – |
Interested in finding out which patents are expiring soon? Fill out the form below, and we’ll provide the details.
This revenue map changes how patent risk should be prioritized. A near-term expiry for a low-exposure product may be less urgent than a later-decade challenge against a growth asset. Conversely, a product such as Linzess becomes strategically visible because the exclusivity and patent timelines compress into a near-term window.
Orange Book timing separates runway assets from near-term watchlist assets
When regulatory exclusivity and latest listed patent expiry are compared product by product, AbbVie’s portfolio becomes easier to interpret. Some assets retain several years of patent runway beyond exclusivity. Others show much tighter alignment, making generic, 505(b)(2), or Paragraph IV activity more relevant.
| Drug | NDA | Exclusivity date | Latest listed patent expiry | Strategic reading |
| Rinvoq | 211675 | May 18, 2026 | Jan. 15, 2031 | Longer runway; monitor continuations and secondary patents. |
| Venclexta | 208573 | May 15, 2026 | May 26, 2030 | Patent runway extends beyond exclusivity; watch challenges closer to 2030. |
| Linzess | 202811 | Jun. 12, 2026 | Aug. 30, 2026 | Near-term watchlist because exclusivity and key patent expiry are close. |
| Vraylar | 204370 | Dec. 18, 2028 | Dec. 16, 2028 | Late-decade target because exclusivity and patent expiry align. |
Linzess is the clearest near-term case study
Linzess is the most concrete near-term example in the analyzed set. The product is used for irritable bowel syndrome with constipation and chronic idiopathic constipation, and it is marketed in the U.S. through AbbVie’s collaboration with Ironwood Pharmaceuticals. In the analyzed data, Linzess has a regulatory exclusivity date of June 12, 2026, while key patent US7304036B2 expires shortly after on August 30, 2026.
| Linzess indicator | Detail |
| Drug / ingredient | Linzess (linaclotide) |
| Therapeutic use | Irritable bowel syndrome with constipation and chronic idiopathic constipation |
| Commercial signal | Ironwood expects full-year 2026 U.S. Linzess net sales of $1.125B-$1.175B |
| Regulatory exclusivity | I-921, expiring June 12, 2026 |
| Key listed patent | US7304036B2, expiring August 30, 2026 |
For generic companies, this timing makes Linzess a visible near-term opportunity candidate. However, the opportunity should not be presented as automatic. Any entry strategy still depends on the complete Orange Book patent set, Paragraph IV positioning, first-filer dynamics, regulatory pathway, settlement history, manufacturing readiness, labeling constraints, and any new patent or exclusivity updates before launch.
For AbbVie, Linzess highlights the importance of lifecycle management, secondary patent coverage, litigation readiness, contracting strategy, and post-expiry market-transition planning.
Litigation reveals which assets AbbVie is willing to defend
A patent portfolio is not measured only by what is filed or granted. It is also measured by what a company chooses to enforce. In the analyzed litigation data, AbbVie’s filing activity increased after 2022, accelerated in 2023, and remained elevated in 2024 before declining in the partial 2025-2026 view. The decline should be presented cautiously unless the dataset is complete for those periods.
This matters because litigation often reveals which products AbbVie considers strategically important enough to defend. Enforcement signals can help competitors distinguish between patents that are merely present and patents that are likely to shape launch timing, settlement negotiations, and freedom-to-operate strategy
| Product / product group | Cases | Strategic reading |
| Elagolix sodium | 6 | Highest litigation concentration in the set; monitor claim scope and case outcomes. |
| Viberzi | 5 | Significant enforcement history; watch settlement and exclusivity implications. |
| Orilissa | 4 | Litigation aligns with asset-level defensive priority. |
| Qulipta | 4 | Enforcement signal around a growth-relevant migraine asset. |
| Ubrelvy | 2 | Lower count, but still relevant because of migraine-franchise importance. |
| Humira biosimilar | 2 | Residual biosimilar-defense relevance in the post-Humira period. |
Product-level risk and opportunity matrix
The strongest way to make the article actionable is to combine commercial exposure, regulatory exclusivity, patent expiry, and enforcement posture into one view. This avoids treating every patent count or expiry date as equally important.
| Product | Protection signal | Entry signal | Strategic interpretation |
| Linzess | Exclusivity and a key listed patent expire close together in 2026. | Near-term generic candidate. | Refresh Orange Book listings, Paragraph IV activity, and litigation status before action. |
| Rinvoq | Patent protection extends beyond 2026 exclusivity. | Longer runway. | Monitor continuation activity, secondary patents, and challenges. |
| Venclexta | Latest listed patent expiry extends beyond exclusivity. | Delayed entry window. | Watch patent challenges and settlement activity closer to 2030. |
| Vraylar | Exclusivity and patent expiry align in late 2028. | Potential late-decade opportunity. | Important ANDA and litigation-monitoring target as 2028 approaches. |
| Qulipta / Ubrelvy | Litigation activity appears in the analyzed set. | Higher-friction target. | Enforcement activity suggests strategic importance within the migraine franchise. |
What competitors and IP teams should monitor next
AbbVie’s portfolio illustrates a broader pharma reality: patent cliffs rarely appear suddenly. They become visible years in advance when teams monitor the right signals consistently.
• New U.S. patent publications, continuations, divisionals, and claim amendments around key growth assets.
• Grant velocity, claim scope, terminal disclaimers, and prosecution-history narrowing.
• Maintenance-fee lapses, abandonments, reissue activity, and family-level attrition.
• Orange Book patent additions, removals, use-code changes, exclusivity-code updates, and delistings.
• Paragraph IV notices, ANDA filings, 505(b)(2) activity, first-filer dynamics, and tentative approvals.
• District court filings, PTAB challenges, claim-construction orders, settlements, and appeal outcomes.
• Revenue concentration, indication expansion, label changes, formulary shifts, and AbbVie’s commercial-priority signals.
• Competitor activity around formulations, polymorphs, dosing regimens, methods of use, combinations, and delivery systems.
The bigger lesson: patent intelligence must move from static reports to live monitoring
The strategic value in AbbVie’s portfolio is not hidden in any single database. It emerges when patent-office data, FDA listings, court records, regulatory timelines, product revenue, and family-level portfolio logic are connected at the product level.
That is where a real-time monitoring workflow becomes more useful than a one-off patent landscape. For an IP or competitive-intelligence team, the goal is not only to know when a patent expires; it is to know when the assumptions around that expiry have changed. A platform such as Elixir can support this shift by centralizing alerts for patent surveillance, prosecution events, patent expiry tracking, Orange Book changes, litigation developments, ANDA signals, and portfolio-risk updates.
For AbbVie, the next phase will be defined by how effectively it protects growth assets such as Rinvoq, Vraylar, Venclexta, Qulipta, and Ubrelvy while managing tighter expiry windows such as Linzess. For competitors, the opportunity lies in identifying the exact points where exclusivity, patent life, litigation posture, and commercial urgency begin to converge.
Book an Elixir demo to see the full insights.
